SIGN UP

top stories

Teenager dies after receiving Sarepta therapy; Immunovant gets Phase 3 win, but shifts focus; Alnylam’s big moment; and more

6 hours ago

Liver cancer drug combo gets second FDA rejection over manufacturing issues

17 hours ago

Alnylam hopes its broad ATTR-CM label can give Amvuttra an edge in heart disease

21 hours ago

Latest

Most read

Trump think tank resurrects international drug pricing model to go after 'global freeloading'

21 hours ago

BARDA cancels annual biomedical event for industry, government reps

22 hours ago

The buildup to Chimerix's $935M exit to Jazz, with more than half a dozen parties intrigued

Yesterday

FDA approves Novartis’ Fabhalta in another rare kidney disease

Yesterday

see latest stream

People

Calley Means joins White House as a special government employee, will assist with MAHA policies

Yesterday

Cargo Therapeutics scraps R&D pipeline, axes bulk of workforce as it looks for an exit

3 days ago

Stem cell company bit.bio cuts quarter of staff, drops therapeutics focus

3 days ago

Financing

SV Health Investors nabs $250M to fund dementia-focused biotechs

Yesterday

Ascendis’ China joint venture, Visen Pharmaceuticals, prices $86M Hong Kong IPO

Yesterday

Flagship's Ampersand gets Eli Lilly's support in $65M Series B

3 days ago

Startups

CRISPR company Arbor raises $73.9M to test therapy in clinical trials

4 days ago

Sofinnova Partners lands €165M, backed by big pharma, to build early-stage biotechs in Europe

4 days ago

George Church spinout developing genomically recoded organisms cuts most employees

5 days ago

Deals

AstraZeneca broadens presence in China, promising $8B+ to Harbour and Syneron

Yesterday

Paratek boosts commercial portfolio in move to buy Optinose and its nasal spray

2 days ago

Sanofi to pay $600M upfront for Dren Bio’s bispecific B cell depleter

2 days ago

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SIGN UP NOW

Subscribe to Endpoints News

In FocusSee all

Illumina was built on DNA. Its future could be biology’s next big wave

2 days ago

A California health tech company is letting AI run medical visits, from intake to diagnosis

2 days ago

Ahead of FDA decision, Alnylam faces the big question: Can it make money?

3 days ago

Inside NYC’s waitlist-only health tech club, where young professionals find both friends and jobs

Last week

Endpoints Standouts

How the world's biggest pharma and biotech companies paid their typical worker in 2023

8 months ago

In biotech's uneven recovery, 50 startups raised megarounds in first half of 2024

8 months ago

Biopharma leaders charting a path for the industry's LGBTQ+ community

9 months ago

Peter Marks single-handedly approved Sarepta’s gene therapy — what does that mean for everyone else?

9 months ago

Peer review See all

Mar

21

BridgeBio, Editas finance chiefs depart; Former FDA No. 2 joins Recursion's board

Mar

14

Merck diversity leader to retire this summer; Geron seeks commercial chops for next CEO

Mar

7

Tune’s CEO search ends as John McHutchison takes top spot; More from Pfizer’s leadership makeover

Feb

28

Pfizer vet William Pao’s next venture; Sanofi’s computational science exec leaves

Feb

21

Merck KGaA tees up changes to leadership team; Ex-CVS Health CEO joins Thermo Fisher’s board

Pharma channel feed

Yesterday

Johnson & Johnson earmarks $55B to boost US capacity

Johnson & Johnson is planning to invest $55 billion to build up its US footprint over the next four years, becoming the latest pharma company to pour billions into the country.

READ MORE

Updated: FDA approves Alnylam’s Amvuttra in ATTR-CM, kicking off competition with Pfizer, BridgeBio

Yesterday

CDC vaccine meeting, delayed earlier this year, is rescheduled

Yesterday

latest in Pharma

Akero exec calls FDA's accelerated approval guidance for MASH drugs 'bizarre'

Yesterday

Novo Nordisk says new early R&D structure will ‘future-proof’ its business

Yesterday

Novartis touts Zolgensma data in older kids as it readies regulatory filings

2 days ago

Gilead stock slips as HHS denies reports of HIV funding cuts

2 days ago

Pfizer fully exits Sensodyne maker Haleon in $3.3B stake sale

3 days ago

see latest stories

Marketing channel feed

3 weeks ago

Novo Nordisk slashes Wegovy price by nearly two-thirds for cash-paying patients

Novo Nordisk cut the price of its weight loss blockbuster Wegovy by nearly two-thirds for certain patients paying outside of insurance, following a similar move by Eli Lilly.

READ MORE

Misleading exhibit booth panel lands NJ drugmaker an untitled letter from FDA

3 weeks ago

Eli Lilly expands Zepbound single-dose vial options at lower price

4 weeks ago

latest in Marketing

J&J's new cancer combo beats AstraZeneca's Tagrisso on survival in lung trial

2 months ago

Drugs are approved — and made available — faster in US than most of EU, data show

3 months ago

Novartis bolsters Fabhalta data in competition with AstraZeneca

3 months ago

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

4 months ago

FDA says Merz's social media promotion with Nate Berkus is 'misleading'

4 months ago

see latest stories

FDA+ channel feed

Yesterday

Two-thirds of recent rare disease drugs relied on just one trial, plus confirmatory evidence, FDA team finds

New research published by FDA authors found that 67% of non-oncologic rare disease marketing applications approved between 2020 and 2023 used only one clinical trial plus confirmatory ...

READ MORE

DOJ lawyers defend abortion pill restrictions in new court filing

2 days ago

FDA staff return to White Oak campus en masse after Trump administration push

4 days ago

latest in FDA+

All selected drugmakers agree to second round of price negotiations under the IRA

5 days ago

Post-Hoc: Kennedy's anti-vaccine actions shouldn't surprise anyone

5 days ago

'It’s the law’: Dr. Oz says he would defend Medicare drug price negotiations

Last week

Updated: White House pulls Weldon's nomination to lead CDC at last minute

Last week

FDA’s medical review departments remain untouched (for now) by Musk’s cuts

Last week

see latest stories

Manufacturing channel feed

Yesterday

AstraZeneca puts $2.5B toward first vaccine factory and second R&D site in China

AstraZeneca is again boosting its manufacturing footprint in China, this time making a $2.5 billion investment to build its first vaccine plant and second R&D facility in the country.

READ MORE

Merck to lay off 163 workers in Pennsylvania; Delpharm gets $60M from Canadian government

2 days ago

WuXi AppTec's US revenue growth continues to dip in post-Biosecure environment

4 days ago

latest in Manufacturing

Recipharm hits record revenue for 2024, eyes GLP-1 contracts for growth

Last week

Sutro slashes workforce in half, changes CEO and closes factory

Last week

Canada pitches in to Entos' facility build; Vetter expands in Germany

Last week

Viking Therapeutics taps CordenPharma to manufacture its obesity drugs

Last week

Legend to double Carvykti production as it targets blockbuster status

Last week

see latest stories